1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. BioMarin Pharmaceutical Acquires Inozyme Pharma

M&A Deal Summary

BioMarin Pharmaceutical Acquires Inozyme Pharma

On May 16, 2025, BioMarin Pharmaceutical acquired life science company Inozyme Pharma for 270M USD

Acquisition Highlights
  • This is BioMarin Pharmaceutical’s 2nd transaction in the Life Science sector.
  • This is BioMarin Pharmaceutical’s 2nd largest (disclosed) transaction.
  • This is BioMarin Pharmaceutical’s 2nd transaction in the United States.
  • This is BioMarin Pharmaceutical’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2025-05-16
Target Inozyme Pharma
Sector Life Science
Buyer(s) BioMarin Pharmaceutical
Deal Type Add-on Acquisition
Deal Value 270M USD
Advisor(s) Centerview Partners (Financial)
Goodwin Procter (Legal)

Target

Inozyme Pharma

Boston, Massachusetts, United States
Inozyme Pharma is a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. The company's lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. It has demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency. Inozyme Pharma was formed in 2015 and is based in Boston, Massachusetts.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

BioMarin Pharmaceutical

San Rafael, California, United States
Category Company
Founded 1996
Sector Life Science
Employees3,040
Revenue 2.9B USD (2024)
DESCRIPTION
BioMarin's corporate headquarters in San Rafael, California.
BioMarin's corporate headquarters in San Rafael, California.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. BioMarin Pharmaceutical was founded in 1996 and is based in San Rafael, California.

DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 3 of 3
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2025 M&A 1 of 1
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-11-24 Prosensa

Leiden, Netherlands

Prosensa is an operator of a biotechnology company that uses a unique and revolutionary licensed technology platform that makes use of so-called exon skipping for correcting mutated RNA. Prosensa company primarily targets Duchenne Muscular Dystrophy (DMD) disorder, against which it has already developed two products that are currently in clinical phase I / II. Prosensa was founded in 2002 and is based in Leiden, Netherlands.

Buy $680M
Mergr

Solution for

Product

Company

Legal